Contemporary pathology of prostate cancer

Urologic Clinics of North America

Volumn 30, Issue 2, 2003, Pages 181-207

  Bostwick, David G ^a,b   Qian, Junqi ^a   Schlesinger, Cory ^a  

^a BOSTWICK LABORATORIES   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER INVASION; CELL PROLIFERATION; CELL STRUCTURE; HISTOPATHOLOGY; HUMAN; NEEDLE BIOPSY; PATHOLOGICAL ANATOMY; PRECANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; TISSUE FIXATION; TISSUE SECTION; TUMOR VOLUME;

EID: 0037407495     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00189-1     Document Type: Review

References (215)

1. Renshaw AA. Adequate tissue sampling of prostate core needle biopsies. Am J Clin Pathol 1997;107(1):26-9.
2. Reyes AO, Humphrey PA. Diagnostic effect of complete histologic sampling of prostate needle biopsy specimens. Am J Clin Pathol 1998;109(4):416-22.
3. Brat DJ, et al. How often are diagnostic features missed with less extensive histologic sampling of prostate needle biopsy specimens? Am J Surg Pathol 1999;23(3):257-62.
4. Iczkowski KA, et al. Needle core length in sextant biopsy influences prostate cancer detection rate. Urology 2002;59(5):698-703.
5. Bostwick DG, Montironi R, Sesterhenn IA. Diagnosis of prostatic intraepithelial neoplasia: Prostate Working Group/consensus report. Scand J Urol Nephrol Suppl 2000;205:3-10.
6. Epstein JI, et al. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 1995;19(8):873-86.
7. Bostwick DG. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol 1996;30(2):145-52.
8. Montironi R, et al. Origins of prostate cancer. Cancer 1996;78(2):362-5.
9. Cheng L, et al. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res 1998;58(3):389-91.
10. Steiner MS. High grade prostatic intraepithelial neoplasia is a disease. Curr Urol Rep 2001;2(3):195-8.
11. Bostwick DG. Prostatic intraepithelial neoplasia. Curr Urol Rep 2000;1(1):65-70.
12. Montironi R, Santinelli A, Mazzucchelli R. Prostatic intraepithelial neoplasia and prostate cancer. Panminerva Med 2002;44(3):213-20.
13. Montironi R, Mazzucchelli R, Scarpelli M. Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann N Y Acad Sci 2002;963:169-84.
14. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986;17(1):64-71.
15. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987;59(4):788-94.
16. Haussler O, et al. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol 1999;30(9):1077-86.
17. Ramos CG, et al. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. J Urol 1999;162(5):1587-90.
18. Feneley MR, Busch C. Precursor lesions for prostate cancer. J R Soc Med 1997;90(10):533-9.
19. Hoedemaeker RF, et al. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer 1999;85(1):145-52.
20. Langer JE, et al. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996;155(1):228-31.
21. Harvei S, et al. Is prostatic intraepithelial neoplasia in the transition/central zone a true precursor of cancer? A long-term retrospective study in Norway. Br J Cancer 1998;78(1):46-9.
22. Skjorten FJ, et al. Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate. Cancer 1997;79(6):1172-9.
23. Berner A, Skjorten FJ, Fossa SD. Follow-up of prostatic intraepithelial neoplasia. Eur Urol 1996;30(2):256-60.
24. Perachino M, et al. Results of rebiopsy for suspected prostate cancer in symptomatic men with elevated PSA levels. Eur Urol 1997;32(2):155-159.
25. Gaudin PB, et al. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology 1997;49(4):558-63.
26. Cheng L, et al. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol 1999;23(7):803-8.
27. Pacelli A, Bostwick DG. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology 1997;50(3):355-9.
28. Borboroglu PG, et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000;163(1):158-62.
29. Yang CR, et al. Unsuspected prostate carcinoma and prostatic intraepithelial neoplasm in Taiwanese patients undergoing cystoprostatectomy. Mol Urol 1999;3(1):33-9.
30. Mai KT, et al. Incidental prostatic adenocarcinomas and putative premalignant lesions in TURP specimens collected before and after the introduction of prostrate-specific antigen screening. Arch Pathol Lab Med 2000;124(10):1454-6.
31. Wills ML, et al. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology 1997;49(3):367-73.
32. Sakr WA, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150(2 Pt 1):379-85.
33. Sakr WA, et al. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephrol Suppl 2000;205:11-8.
34. Billis A. Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology 1986;28(4):324-9.
35. Bostwick DG, et al. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 1993;24(3):298-310.
36. Montironi R, et al. Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance. J Clin Pathol 2000;53(9):655-65.
37. Reyes AO, et al. Unusual histologic types of high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 1997;21(10):1215-22.
38. Berman DM, Yang J, Epstein JI. Foamy gland high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 2000;24(1):140-4.
39. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996;29(2):117-34.
40. Aquilina JW, et al. High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer. Prostate 1998;36(3):189-193.
41. Waters DJ, Bostwick DG. Prostatic intraepithelial neoplasia occurs spontaneously in the canine prostate. J Urol 1997;157(2):713-6.
42. Bostwick DG, Ramnani D, Qian J. Prostatic intraepithelial neoplasia: animal models 2000. Prostate 2000;43(4):286-94.
43. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998;95(26):15382-7.
44. Kasper S, et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998;78(3):319-33.
45. Aboseif S, et al. The significance of prostatic intraepithelial neoplasia. Br J Urol 1995;76(3):355-9.
46. Krishnamurthi V, Klein EA, Levin HS. Probability of prostate cancer detection following diagnosis of prostatic intraepithelial neoplasia (PIN). J Urol 1997;157(4 Suppl):366.
47. Davidson D, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995;154(4):1295-9.
48. Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol 1995;153(5):1496-8.
49. Weinstein MH, Epstein JI. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 1993;24(6):624-9.
50. Keetch DW, et al. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995;154(2 Pt 1):347-51.
51. Raviv G, et al. Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. J Urol 1996;156(3):1050-4; discussion, 1054-5.
52. Berner A, et al. DNA distribution in the prostate. Normal gland, benign and premalignant lesions, and subsequent adenocarcinomas. Anal Quant Cytol Histol 1993;15(4):247-52.
53. Shepherd D, et al. Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol 1996;156(2 Pt 1):460-2; discussion, 462-3.
54. Pacelli A, Bostwick DG. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology 1997;50(3):355-9.
55. Gaudin PB, et al. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology 1997;49(4):558-563.
56. Balaji KC, et al. Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. J Urol 1999;162(3 Pt 1):753-7.
57. Ferguson J, et al. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994;44(1):91-5.
58. Vailancourt L, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996;20(1):86-93.
59. Yang XJ, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999;53(4):696-700.
60. Slem CE, et al. The effect of finasteride on prostate gland peripheral zone histology and proliferation rates in men at high risk for prostate cancer. J Urol 1997;157:228-32.
61. Gaudin PB, et al. Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. Am J Surg Pathol 1999;23(9):1021-31.
62. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med 2000;124(1):98-107.
63. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991;68(4):821-8.
64. Greenlee RT, et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7-33.
65. Parker CC, Gospodarowicz M, Warde P. Does age influence the behaviour of localized prostate cancer? BJU Int 2001;87(7):629-37.
66. Henson DE, Hutter RV, Farrow G. Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the Cancer Committee, College of American Pathologists Task Force on the Examination of Specimens Removed from Patients with Prostate Cancer. Arch Pathol Lab Med 1994;118(8):779-83.
67. Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomical and Surgical Pathology. Hum Pathol 1996;27(4):321-3.
68. Sakr WA, et al. Staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer 1996;78(2):366-8.
69. Hall GS, Kramer CE, Epstein JI. Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol 1992;16(4):315-24.
70. Schmid HP, McNeal JE. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am J Surg Pathol 1992;16(2):184-91.
71. Haggman M, et al. Characterization of localized prostatic cancer: distribution, grading and pT-staging in radical prostatectomy specimens. Scand J Urol Nephrol 1993;27(1):7-13.
72. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol 1994;10(1):60-72.
73. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18(8):796-803.
74. Bostwick DG, et al. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 1994;18(12):1240-6.
75. Bostwick DG. Significance of tumor volume in prostate cancer. Urol Ann (Paris) 1994;8:1-22.
76. Bostwick DG, Vonk J, Picado A. Pathologic changes in the prostate following contemporary 18-gauge needle biopsy: no apparent risk of local cancer seeding. J Urol Pathol 1994;2:203-12.
77. Donohue RE, Miller GJ. Adenocarcinoma of the prostate: biopsy to whole mount. Denver VA experience. Urol Clin North Am 1991;18(3):449-52.
78. Cohen MB, Soloway MS, Murphy WM. Sampling of radical prostatectomy specimens. How much is adequate? Am J Clin Pathol 1994;101(3):250-2.
79. Bostwick DB, Dundore PA. Biopsy pathology of the prostate. London: Chapman & Hall Medical; 1997.
80. Varma M, et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med 2002;126(5):554-61.
81. Helpap B. Observations on the number, size and localization of nucleoli in hyperplastic and neoplastic prostatic disease. Histopathology 1988;13(2):203-11.
82. Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17(4):222-72.
83. Alline KM, Cohen MB. Signet-ring cell carcinoma of the prostate. Arch Pathol Lab Med 1992;116(1):99-102.
84. Guerin D, Hasan N, Keen CE. Signet ring cell differentiation in adenocarcinoma of the prostate: a study of five cases. Histopathology 1993;22(4):367-371.
85. Torbenson M, et al. Prostatic carcinoma with signet ring cells: a clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. Mod Pathol 1998;11(6):552-9.
86. Kojima M, Troncoso P, Babaian RJ. Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. Urology 1995;45(5):807-12.
87. Thickman D, et al. Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer. J Urol 1996;156(1):110-3.
88. Cookson MS, et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997;157(2):559-62.
89. Spires SE, et al. Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med 1994;118(7):705-8.
90. Steinberg DM, et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21(5):566-76.
91. Aihara M, et al. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994;43(1):60-6; discussion, 66-7.
92. Sakr WA, et al. Epidemiology of high-grade prostatic intraepithelial neoplasia, Scand J Urol Nephrol Suppl 2000;205:11-8.
93. Herman CM, et al. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 2001;25(5):657-60.
94. Villers AA, et al. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol 1990;143(6):1183-7.
95. Epstein JI, Carmichael M, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 1993;149(5):1040-5.
96. Ohori M, et al. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 1993;17(12):1252-61.
97. Del Rosario AD, et al. Sulfur-rich prostatic intraluminal crystalloids: a surgical pathologic and electron probe x-ray microanalytic study. Hum Pathol 1993;24(11):1159-67.
98. Molberg KH, Mikhail A, Vuitch F. Crystalloids in metastatic prostatic adenocarcinoma. Am J Clin Pathol 1994;101(3):266-8.
99. Tressera F, Barastegui C. Intraluminal crystalloids in metastatic prostatic carcinoma. Am J Clin Pathol 1995;103(5):665.
100. Bostwick DG, Wollan P, Adlakha K. Collagenous micronodules in prostate cancer. A specific but infrequent diagnostic finding. Arch Pathol Lab Med 1995;119(5):444-7.
101. Rubin MA, et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3, N0) prostate cancer. Hum Pathol 2000;31(4):504-8.
102. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 1993;17(4):336-41.
103. de la Taille A, et al. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999;54(6):1039-1043.
104. de la Taille A, et al. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy? J Urol 1999;162(1):103-6.
105. Merrick GS, et al. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J 2001;7(5):404-12.
106. Egan AJ, Bostwick DG. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 1997;21(12):1496-500.
107. McIntire TL, Franzini DA. The presence of benign prostatic glands in perineural spaces. J Urol 1986;135(3):507-9.
108. O'Malley KJ, et al. Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 2002;59(1):85-90.
109. Maru N, et al. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol 2001;32(8):828-33.
110. Sebo TJ, et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 2002;26(4):431-9.
111. Ozcan F. Correlation of perineural invasion on radical prostatectomy specimens with other pathologic prognostic factors and PSA failure. Eur Urol 2001;40(3):308-12.
112. Endrizzi J, Seay T. The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer. BJU Int 2000;85(6):696-8.
113. Bahnson RR, et al. Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate 1989;15(2):149-55.
114. Salomao DR, Graham SD, Bostwick DG. Microvascular invasion in prostate cancer correlates with pathologic stage. Arch Pathol Lab Med 1995;119(11):1050-4.
115. Schroder FH, et al. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
116. The TNM classification of prostate cancer: a discussion of the 1992 classification. The British Association of Urological Surgeons TNM Subcommittee. Br J Urol 1995;76(3):279-85.
117. Montie JE. Staging of prostate cancer. Current TNM classification and future prospects for prognostic factors. Cancer 1995;75:1814-8.
118. Donaldson ES, Glenn JF. The 1995 staging requirement for approved cancer programs. Urology 1996;47(4):455-6.
119. Epstein JI, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271(5):368-74.
120. Scaletscky R, et al. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. J Urol 1994;152(1):129-131.
121. Jhaveri FM, et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999;17(10):3167-72.
122. Theiss M, et al. Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate 1995;27(1):13-7.
123. Cheng L, et al. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999;86(9):1775-82.
124. Ohori M, et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154(5):1818-24.
125. McNeal JE, Bostwick DG. Anatomy of the prostate: implications for disease. In: Bostwick DG, editor. Pathology of the prostate. New York: Churchill Livingstone; 1990. p. 1-14.
126. Epstein JI, et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20(3):286-92.
127. Schellhammer PF. Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology 1988;31(3):191-7.
128. Stein A, et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992;147(3 Pt 2):942-6.
129. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990;144(5):1180-4.
130. Lerner SE, Blute ML, Zincke H. Primary surgery for clinical stage T3 adenocarcinoma of the prostate. In: Vogelzang NJ, et al, editors. Comprehensive textbook of genitourinary oncology. 1996,: Baltimore: Williams and Wilkins; 1996. p. 803-11.
131. Scardino PT. Early detection of prostate cancer. Urol Clin North Am 1989;16(4):635-55.
132. Scardino PT, et al. The prcgnostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol 1986;135(3):510-6.
133. Epstein JI, et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149(6):1478-81.
134. Cheng L, et al. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol 2000;13(2):113-8.
135. Blute ML, et al. Pathologic classification of prostate carcinoma: the impact of margin status. Cancer 1998;82(5):902-8.
136. Stamey TA, et al. Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 199;143(6):1166-72; discussion, 1172-3.
137. Jones EC. Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 1990:144(1):89-93.
138. Catalona WJ, Dresner SM. Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function. J Urol 1985;134(6):1149-51.
139. Voges GE, et al. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer 1992;69(2):520-6.
140. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152(5 Pt 2):1826-30.
141. Ackerman DA, et al. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993;150(6):1845-50.
142. Schmid HP, et al. Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels. Urology 1996;47(5):699-703.
143. Hammerer P, Huland H, Sparenberg A. Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. Eur Urol 1992;22(4):281-7.
144. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992;148(3):829-32.
145. Stamey TA, et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 Suppl):933-8.
146. Haggman M, et al. Standardized in vitro mapping with multiple core biopsies of total prostatectomy specimens: localization and prediction of tumour volume and grade. Br J Urol 1994;74(5):617-25.
147. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994;44(6):862-7; discussion, 867-8.
148. Cupp MR, et al. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153(5):1543-8.
149. Daneshgari F, et al. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 1995;45(4):604-9.
150. Humphrey PA, Baty J, Keetch D. Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostate carcinoma in radical prostatectomy tissues. Cancer 1995;75:1842-9.
151. Weldon VE, et al. Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol 1995;154(3):1074-1077.
152. Bruce RG, et al. Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. Urology 1996;48(1):75-9.
153. Goto Y, et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156(3):1059-63.
154. Ravery V, et al. Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma? Cancer 1996;78(5):1079-1084.
155. Lee WR, Hanlon A, Hanks GE. Do the results of systematic biopsies predict outcome in patients with T1-T2 prostate cancer treated with radiation therapy alone? Urology 1996;47(5):704-7.
156. D'Amico AV, et al. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score 3.0.CO; 2-9. Cancer 2000;89(8):1810-7.
157. Freedland SJ, et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002;167(2 Pt 1):516-520.
158. Noguchi M, et al. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol 2000;164(5):1596-1600.
159. Wheeler TM, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 1998;29(8):856-62.
160. Stamey TA, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281(15):1395-400.
161. Babaian RJ, et al. Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol 1995;154(5):1808-12.
162. Renshaw AA, et al. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998;83(4):748-52.
163. Dugan JA, et al. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275(4):288-94.
164. Humphrey PA, Vollmer RT. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 1997;10(4):326-33.
165. Carvalhal GF, et al. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 2000;89(6):1308-14.
166. Schned AR, et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol 1996;20(12):1501-6.
167. Goldstein NS, et al. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the "vanishing cancer phenomenon". Am J Surg Pathol 1995;19(9):1002-9.
168. DiGiuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol 1997;21(2):174-8.
169. Bostwick DG, et al. Prognostic factors in prostate cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000;124(7):995-1000.
170. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol 1999;23(7):781-5.
171. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 1999;23(12):1471-9.
172. Ro JY, et al. Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies. Hum Pathol 1990;21(6):593-600.
173. McNeal JE, et al. Mucinous differentiation in prostatic adenocarcinoma. Hum Pathol 1991;22(10):979-88.
174. Efros MD, et al, Unusual primary prostatic malignancies. Urology 1992;39(5):407-10.
175. Ishizu K, et al. [Mucinous adenocarcinoma of the prostate with good response to hormonal therapy: a case report]. Hinyokika Kiyo 1991;37(9):1057-60.
176. Teichman JM, Shabaik A, Demby AM. Mucinous adenocarcinoma of the prostate and hormone sensitivity. J Urol 1994;151(3):701-2.
177. Pinder SE, McMahon RF. Mucins in prostatic carcinoma. Histopathology 1990;16(1):43-6.
178. Grignon DJ, O'Malley FP. Mucinous metaplasia in the prostate gland. Am J Surg Pathol 1993;17(3):287-90.
179. Pacelli A, et al. Prostatic adenocarcinoma with glomeruloid features. Hum Pathol 1998;29(5):543-6.
180. Humphrey PA, et al. Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol 1998;22(10):1239-1246.
181. Levi AW, Epstein JI. Pseudohyperplastic prostatic adenocarcinoma on needle biopsy and simple prostatectomy. Am J Surg Pathol 2000;24(8):1039-1046.
182. Egan AJ, Lopez-Beltran A, Bostwick DG. Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. Am J Surg Pathol 1997;21(8):931-5.
183. Cina SJ, Epstein JI. Adenocarcinoma of the prostate with atrophic features. Am J Surg Pathol 1997;21(3):289-95.
184. Kaleem Z, et al. Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens. Am J Clin Pathol 1998;109(6):695-703.
185. Miller VA, Reuter V, Scher HI. Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma. Urology 1995;46(1):111-3.
186. Gattuso P, et al. Adenosquamous carcinoma of the prostate. Hum Pathol 1995;26(1):123-6.
187. Armas OA, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18(10):979-91.
188. Civantos F, et al. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 1995;75(7):1634-41.
189. Ellison E, Chuang SS, Zincke H. Prostate adenocarcinoma after androgen deprivation therapy: a comparative study of morphology, morphometry, immunohistochemistry, and DNA ploidy. Pathology Case Reviews 1996;2:36-46.
190. Gaudin PB. Histopathologic effects of radiation and hormonal therapies on benign and malignant prostate tissues. J Urol Pathol 1998;8:55-67.
191. Montironi R, et al. Androgen-deprived prostate adenocarcinoma: evaluation of treatment-related changes versus no distinctive treatment effect with a Bayesian belief network. A methodological approach. Eur Urol 1996;30(3):307-15.
192. Smith DM, Murphy WM. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 1994;73(5):1472-7.
193. Tetu B, et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol 1991;15(2):111-20.
194. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen depri-vation therapy. Urology 1997;49(3A Suppl):16-22.
195. Montironi R, Schulman CC. Pathological changes in prostate lesions after androgen manipulation. J Clin Pathol 1998;51(1):5-12.
196. Grignon DJ, et al. Pathologic handling and reporting of prostate tissue specimens in patients receiving neoadjuvant hormonal therapy: report of the Pathology Committee. Mol Urol 1999;3(3):193-8.
197. Algaba F, et al. Assessment of prostate carcinoma in core needle biopsy-definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996;78(2):376-81.
198. Paterson RF, et al. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy. Mol Urol 1999;3(3):277-86.
199. Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982;6(6):541-51.
200. Cheng L, et al. p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer 1999;85(6):1293-1299.
201. Cheng L, et al. p53 Alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer 1999;35(11):2455-9.
202. Brawer MK, et al. Keratin immunoreactivity as an aid to the diagnosis
203. Grignon DJ, Sakr WA. Histologic effects of radiation therapy and total androgen blockade on prostate cancer. Cancer 1995;75:1837-41.
204. Helpap B, Koch V. Histological and immunohistochemical findings of prostatic carcinoma after external or interstitial radiotherapy. J Cancer Res Clin Oncol 1991;117(6):608-14.
205. Siders DB, Lee F, Mayman DM. Diagnosis of prostate cancer altered by ionizing radiation with and without neoadjuvant antiandrogen hormonal ablation. In: Foster CS, Bostwick DG, editors. Pathology of the prostate. Philadelphia: WB Saunders; 1998. p. 315-26.
206. Siders DB, Lee F. Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound. Hum Pathol 1992;23(4):344-51.
207. Wheeler JA, Zagars GK, Ayala AG. Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer 1993:71(11):3783-7.
208. Cheng L, Lloyd RV, Pisansky TM. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Mod Pathol 1998;11:324-8.
209. Cheng L, Cheville JC, Bostwick DG. Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am J Surg Pathol 1999;23(10):1173-1183.
210. Kuban D, el-Mahdi AM, Schellhammer PF. Prognostic significance of post-irradiation prostate biopsies. Oncology (Huntingt) 1993;7(2):29-38; discussion, 40, 43-4, 47.
211. Letran JL, Brawer MK. Management of radiation failure for localized prostate cancer. Prostate Cancer Prostatic Dis 1998;1:119-27.
212. Prendergast NJ, et al. p53 Immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol 1996;155(5):-1692.
213. Crook JM, et al. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 1997;79(1):81-9.
214. Goldstein NS, et al. The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure. Am J Clin Pathol 1998;110(6):765-75.
215. Sheaff MT, Baithun SI. Effects of radiation on the normal prostate gland. Histopathology 1997;30(4):341-8.